ArticlePreventive medicine reports2017
Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment.
Article in Preventive medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Cost-utility analysis of using high-intensity statin among post-hospitalized acute coronary syndrome patients.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Article
- Mannose-Binding Lectin Reduces Oxidized Low-Density Lipoprotein Induced Vascular Endothelial Cells Injury by Inhibiting LOX1-ox-LDL Binding and Modulating Autophagy.Biomedicines · 2023Article
- Implementation of a Patient Questionnaire in Community Pharmacies to Improve Care for Patients Using Combined Antithrombotic Therapy: A Qualitative Study.Pharmacy (Basel, Switzerland) · 2023Article
- Cardiovascular event rate and death in high-risk secondary prevention patient cohort in Finland: A registry study.Clinical cardiology · 2022Article
- How and Why Patients Adhere to a Prescribed Cardiac Rehabilitation Program: A Longitudinal Phenomenological Study of Patients with Acute Coronary Syndrome.International journal of environmental research and public health · 2022Article
- Unintentional guideline deviations in hospitalized patients with two or more antithrombotic agents: an intervention study.European journal of clinical pharmacology · 2021Article
- Cardiovascular Event Rates After Myocardial Infarction or Ischaemic Stroke in Patients with Additional Risk Factors: A Retrospective Population-Based Cohort Study.Advances in therapy · 2021Article
- Landscape of Lipid Management Following an Acute Coronary Syndrome Event: Survey of Canadian Specialists.CJC open · 2020Article
- Natural language processing and machine learning to enable automatic extraction and classification of patients' smoking status from electronic medical records.Upsala journal of medical sciences · 2020Article
- The Impact of Coexistence of Smoking and Diabetes on the Coronary Artery Severity and Outcomes following Percutaneous Coronary Intervention: Results from the 1International journal of vascular medicine · 2020Article
- Incidence and risk factors for recurrent cardiovascular disease in middle-eastern adults: a retrospective study.BMC cardiovascular disorders · 2019Article
- Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data.European heart journal. Quality of care & clinical outcomes · 2019Article
- Epidemiology of Pulmonary Fibrosis: A Cohort Study Using Healthcare Data in Sweden.Pulmonary therapy · 2019Article
- Underutilization of Statin Therapy for Secondary Prevention of Cardiovascular Disease Among Older Adults.Population health management · 2019Article
- Role of perceived heart risk factors by outpatient population in predicting cardiovascular risk.Journal of cardiovascular and thoracic research · 2019Article
- Hydroxybutyrate promotes the recovery from cerebral infarction by activating Amp-activated protein kinase signaling.Experimental and therapeutic medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several randomized controlled trials have shown a benefit of high-dose intensive statin treatment in reducing risk of death and second cardiovascular disease (CVD) events in patients previously diagnosed with an acute coronary syndrome (ACS). Non-randomized studies in clinical settings support these findings, but large, long-term, observational studies addressing CVD and non-CVD endpoints are lacking. In this retrospective longitudinal study, we followed ACS patients in Sweden during 2001-2012 using national health registry and medical record data. A total of 49,857 patients were identified, of whom 10,092 (20.2%) received high dose statins and 21,174 (42.7%) received no statins. Royston-Parmar parametric time-to-event models were implemented to model hazard for second CVD events and death, stratified by gender and diabetes diagnosis. We found that risk of a second CVD event developed similarly in both treatment groups, but was much higher in the no statin group. Risk of CVD-related death remained relatively constant for the high-statin group, while it increased over time for the no-statin group. Interestingly, males had higher mortality rates in the no-statin group, but not in the high-statin group. All-cause mortality and non-CVD-related death followed similar trends to those observed for CVD-related death. This work provides additional real-world evidence for effect of statins in CVD-related mortality. The hazard functions presented here can provide a basis for future survival modeling and health economic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.